期刊
VIRUSES-BASEL
卷 4, 期 12, 页码 3589-3605出版社
MDPI
DOI: 10.3390/v4123589
关键词
influenza; H5N1; live-attenuated influenza vaccines; cross-protection; adjuvants
类别
资金
- National Natural Science Foundation of China [81071346, 81172738]
- National High Technology Research and Development Program of China (863 Program) [2010AA022905, 2010AA022908, 2010AA022910]
Several global outbreaks of highly pathogenic avian influenza (HPAI) H5N1 virus have increased the urgency of developing effective and safe vaccines against H5N1. Compared with H5N1 inactivated vaccines used widely, H5N1 live-attenuated influenza vaccines (LAIVs) have advantages in vaccine efficacy, dose-saving formula, long-lasting effect, ease of administration and some cross-protective immunity. Furthermore, H5N1 LAIVs induce both humoral and cellular immune responses, especially including improved IgA production at the mucosa. The current trend of H5N1 LAIVs development is toward cold-adapted, temperature-sensitive or replication-defective vaccines, and moreover, H5N1 LAIVs plus mucosal adjuvants are promising candidates. This review provides an update on the advantages and development of H5N1 live-attenuated influenza vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据